Peptide Show

Can peptides help athletes recover faster from injury? 

When an injury keeps you out of training, the promise of a quicker recovery is hard to ignore. Some of Dr Chris Raynor’s patients are already using peptides by the time they see him. Some even believe a peptide injection reattached a torn tendon. 

Before he became an orthopaedic surgeon, Chris was drafted by the Winnipeg Blue Bombers of the Canadian Football League. Today, he specialises in knee and shoulder reconstruction and breaks down sports injuries for more than 700,000 subscribers on YouTube. 

He joins Richard Skaife to discuss why he doesn’t use BPC-157 in his practice, what athletes risk when they skip rehab, and what evidence would persuade him to recommend it. 
 
He explains: 

■ What animal studies suggest about BPC-157
■ Partial versus full-thickness tendon tears
■ Why an injection can’t replace physio
■ What’s unknown about dosing and long-term safety
■ Who might fund human trials

Chapters

  • (00:00) - Intro with Dr Chris Raynor
  • (01:51) - Why Chris holds off on recovery peptides
  • (04:18) - What would prove BPC-157 works?
  • (06:28) - Peptide access in Canada and the US
  • (09:33) - “I’m already using it, Doc”
  • (10:28) - Can peptides replace physio?
  • (13:10) - Why so many of Chris’s peers are sceptical
  • (16:39) - Can peptides repair a torn rotator cuff?
  • (18:46) - Will peptides become routine treatment?
  • (20:50) - Who will pay for the human trials?

Watch the full episode on YouTube

Further reading

PubMed. An October 2026 review identified three human studies of BPC-157 involving 30 participants. The authors rated the overall certainty of the evidence as very low. Human evidence for BPC-157 in orthopaedic and regenerative medicine

ClinicalTrials.gov. A registered trial compares BPC-157 with placebo after a hamstring strain. Both groups follow the same rehab programme. One of the main outcomes is how soon participants return to unrestricted sport. BPC 157 for Acute Hamstring Muscle Strain Repair

ClinicalTrials.gov. A University of Arkansas trial is designed to test whether BPC-157 improves shoulder strength after rotator cuff repair surgery. No results have been posted. Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery

Insights into Imaging. The arrow in Figure 13B shows where a torn rotator cuff tendon has pulled back. Image credit: Yubran et al. (2024), panel B cropped from Figure 13. View the shoulder MRI · CC BY 4.0

Health Canada. A public advisory on unauthorised injectable peptides sold online, including products labelled BPC-157 and TB-500. Think twice before injecting peptides bought online

Follow Dr Chris Raynor

YouTube: @ChrisRaynorMD
Instagram: @drchrisraynor
Website: drchrisraynor.com

Follow Richard Skaife

LinkedIn: linkedin.com/in/richardskaife/

Peptide Show

Website: Peptide.Show
Instagram: @Peptide.Show
TikTok: @peptide.show
Facebook: Peptide Show
X: @peptideshow
YouTube: @PeptideShow

Peptide Show explores the science, medicine, business, and people shaping the rapidly evolving world of peptides.

Presented by Longr: longr.io

Follow Peptide Show for new episodes every Tuesday.

This podcast is for informational and educational purposes only and does not constitute medical advice. Some compounds discussed in this episode are investigational, unapproved for the uses discussed, or subject to changing regulatory requirements.

Creators and Guests

Host
Richard Skaife
Entrepreneur, Venture Capitalist and CEO of Longr, focused on longevity, health technology and emerging science.
Guest
Dr Chris Raynor
Dr Chris Raynor is a Canadian orthopaedic surgeon specialising in knee and shoulder reconstruction. On his YouTube channel, Not Your Everyday Ortho, he explains sports injuries and recovery.
Editor
Toby Sorabjee
Co-founder and COO of Longr, working across longevity, health technology, investing and media.

What is Peptide Show?

Welcome to the world of Peptides. New episodes every Tuesday.

I'm not against peptides, but

I have so many people
talking to me about using them,

and they tell me, "Well, you know,

I just want to be honest, Doc.

I'm already using it."

And the problem is,
even if you're going to use peptides,

they don't replace the normal treatments.

But when you are talking a significant

full-thickness tear that is retracted,

this is no longer really
a biological problem.

This is a structural problem.

It's like you having a hole in your roof

and then trying to paint
the walls inside your house

and saying that you fixed the problem.

If you've ever heard someone say,

"Have you tried peptides yet?"
and wanted to learn more,

well, you're in the right place.

We bring you a different perspective
every Tuesday,

so like and subscribe
and come along for the journey.

In 1992, the Winnipeg Blue Bombers
picked Chris Raynor

in the Canadian Football League draft.

Today he's an orthopedic surgeon

specializing in knee and shoulder
reconstruction.

You might also know him from YouTube,

where he breaks down sports injuries

for more than 700,000 subscribers.

Chris thinks peptides could

one day have a place
in routine sports medicine,

but for now
he doesn't use them in his practice.

So the question is, why? And what

would it take

for him to recommend them to his patients?

In this conversation,

we explore what the existing studies
can tell us,

why some patients
are turning to injections

instead of physio,

and who might pay for the clinical trials

Chris wants to see.

My guest today is Dr. Chris Raynor.

Welcome to Peptide Show.

Welcome to Peptide Show from Longr.

My name is Richard Skaife.

I'm a venture capitalist and entrepreneur.

My guest today is Chris. Chris,

thank you very much for joining us.

No problem. Thank you for having me.

Greatly appreciate the opportunity
to chat about this.

Not a problem. Now,

you describe yourself as somebody
who is a sort of

peptide agnostic.

And we have a lot of people
who join us on this podcast

who describe themselves
as peptide champions

or peptide evangelists.

What

sort of puts you into

a sort of peptide-agnostic group?

And does that mean you don't work
with peptides at all?

Well, let me say, first of all,

I don't really work a lot with peptides.

Well,

not really at all, because

they're not really
an established part of medicine

in mainstream medicine in Canada,
where I practice.

There are opportunities

for us to use them on a research basis,

but in regular day-to-day medicine,

they're not...

At least, peptides in the way
that people refer to them,

generally speaking,

they're not part of mainstream medicine.

Peptides are part of medicine.

Insulin is... or not insulin,

but, well, insulin being one compound.

And there

are other things that we use
that are part of

peptides as an umbrella

that are commonplace.

But in the parlance
that you're talking about,

where people are talking about TB-500,

BPC-157,

and,

you know, all those types of things,

those aren't part of regular stuff.

So why would I say that I'm agnostic?

Just because when it comes to those,

that latter group that I just mentioned,

I...

there's not

enough research for me to say
that these things are

or are not effective. Obviously,

in animal studies,

there is evidence
that they have some effect.

But we don't have,

you know, robust human studies

in large enough volumes

or with enough standardization
that we can say, "Yes,

this works. It works in this way.

Here's the dose that you need to use."

All of these things.

And so, without having that information,

I just...

I can't really tell people
that either they work

or they do not work.

I can just say it appears
that there may be an effect.

We don't know what the dosing is,
and we don't know

what the long-term effects are.

And so...

Yeah,

you make a really good point there.

I mean, in terms of somebody

who's potentially going to work with them,

you know,

in a clinical setting,

and if we take something like

BPC-157,

you know,

there's a limited amount

of animal data around that.

What would need to happen for you

to get comfortable,

you know, bringing those
into a practice environment?

Given there isn't a sort of...

there isn't a lead sponsor
for that molecule

in the same way that we would see with

a conventional therapeutic

which is going to go through
clinical trials,

how could that data sort of start

to come into fruition?

Well, so number one,

we'd have to have rigorous human trials

which had a large enough volume.

So N needs to be a high enough number.

Like, ten people doesn't count, right?

Like,

we need to have thousands of people
that go through.

We need to have rigorous protocols
to those studies

so that the studies themselves
are standardized.

We need to have
a standardized dosing scheme, right?

We need to know exactly
how much you're using,

for what duration of time,

how often it's being administered.

All of those things
would need to be established

and standardized

so that whatever information we got was

reproducible. And then

we'd have to do that
for a long enough period of time

that we could then say, "Okay, yes,

it has proven to be effective
over this period of time,

and here are some of the results.

Here are some of the negative results

or some of the problems that we have

seen during that time."
Because many of these things that

people talk about
could very well be effective.

But, you know, we don't...

One of the things
that we also don't know is

whether there are long-term side effects.

And so that's something

else that we would need to

have enough volume
and a long enough duration of study

so that we could actually
accumulate that information,

so that we could then report on it,

so we could give people an idea of,

you know, "Is this effective? Okay,

yes, it's effective,

but it has these side effects."

And then people could actually weigh

those various issues appropriately
to make a decision,

an educated decision as to whether

or not they're going to use it.

And do you see this as being a sort of

patient-physician decision? Or

do you see

there being more and more
of the similar levers

that we're seeing, which are being pulled

in the United States,

where very much it's patients
who are driving,

you know,

almost their own self-sovereignty,
their own autonomy?

How do you think it's going to

sort of start to manifest in Canada?

And then one final question
on that same theme is,

where's Health Canada sitting

from a regulatory perspective

versus the FDA? Is there

a potential for a compounding market to

appear in the Canadian market,

or is that

not something which is happening
in your local market?

Well,

I don't think... In my local market,
that's not happening,

the compounding.

I do see, like,

when you compare Canada
to the United States,

I would say that we probably have

a more stringent regulatory mechanism,

because there are lots of things that are

present in the United States,

that are approved in the United States,

that are not in Canada, or that take

substantially longer
to be approved in Canada

than in the United States.

So I think that

that is the difference
between our two markets.

And how I see this playing out,
potentially,

at least in Canada,
is that it will be more of a

doctor-patient relationship type of thing.

And patients may push this so that it,

you know,

it spurs

the regulatory bodies
to take a closer look at this

for consideration. But

I don't see it as being the same

as in the United States, where really

the patients and the market
are pushing this,

and that's kind of fueling
the whole progression.

I see it being
a more orderly and slow process

in Canada,

where they're really looking more
towards the data.

And what is the data saying about it?

What are the risks

and the complications associated with it?

And that is the framework
that I see us moving forward

with.

I don't think that we'll be able
to avoid it

because there is so much,

so much enthusiasm about its use,

about their use online
through social media, that

I don't think it's something that

regulatory bodies
are going to be able to avoid

in Canada. But

I do think they will still take
a more rigorous

and slow approach,

which is different than what's going on

in the United States,

and especially because of people like RFK,

who are very pro-peptide.

And now that he is,

you know, basically

the secretary of health,

you know, he's basically trying
to push things forward

so that they will be less regulated

and more available to people.

And to be honest, I don't...

We said at the start,

I'm agnostic, so I don't...

I'm not against peptides,
but the thing is,

I have so many people
talking to me about using them,

and they tell me, "Well, you know,

I just want to be honest, Doc.

I'm already using it. I'm doing this."

And they

think that what they're doing
is risk-free.

Or if they believe that there are risks,

they underestimate the risks
that are associated.

- And so...
- What would some of those examples be?

I mean,

you hit on
a really interesting point where,

you know, so many doctors are saying

that,

you know,

people come to them for sort of an

after-the-fact consultation.

"I'm already using this medication.

What should I be aware of now
that I'm already using it?"

Which is quite unusual.

I don't think we've ever seen this

in any other field of medicine.

What are some of those examples

of where people are coming to you

and they've already...
Let's call it what it is.

They've already self-prescribed.

Sure. Well,

I think you can probably

categorize these issues into

two categories. So,

first, there's the category

where people are using these things

because they basically want to shortcut

the things that are actually going to help

the problem that they have.

In other words,
they don't want to do the physio,

or they don't want to put in the work,

or they don't want to wait
the duration of time,

so they use them instead.
And the problem is,

even if you're going to use peptides,

they don't replace the normal treatments.

What they do is supplement

those treatments.
And so people who use them

thinking that they can avoid
doing the physio,

they actually just don't do
the things that they

actually need to do

to help their problem
in addition to the peptides.

And so they're losing out on the benefits

of all of those things

and potentially making
their recovery worse,

take longer or just not be appropriate.

- So that's one category.
- We've seen that with GLP-1s.

I mean, I think,

you know,

people

using GLP-1s
but not making lifestyle changes.

They're not adding, you know,

protein in a significant way
to their diet.

They're not doing
the relevant amount of exercise.

There's this sort of mindset that,

you know, the injection

or the pill is all that they need to do.

So,

are we leaning towards,

you know, a world where

peptides are,

ultimately,

more embraced by the medical community,

but then there will be specialists
in different domains

who will look at
sort of augmenting peptides

with the protocol of the domain that

they're most familiar with?

Is that something that's, you know,

looking like a potential future?

Well, I think,

once we have some sort of

standardization

and better acceptance
in the medical community

at large, then I think, yes,

that's what we will have,

those types of scenarios

where we have people using peptides,

but for whatever problem
a person presents with,

they are then

also paired with a specialist in that area

who is going to say,
"The peptide is not the treatment.

It is a part of the treatment,

and it is supplemented
by these other things."

And the treatment as a whole

incorporates all of these things,

of which peptide is just one, right?

Peptide is not the treatment.

It's just one of the additional tools
that we use to

treat the problem you present with.

Indeed. And I mean,

you

just...

You say yourself you're agnostic.

What would you say, if you're looking

at your peers who are practicing medicine,

where would you say
the agnostic percentage sits

versus the pragmatic, enthusiastic,
versus people who are,

you know,
on different degrees of cynicism?

I...

if I were to look probably
to my peer group,

I would say that the

- cynics are probably about 85% to 90%.
- Wow.

Agnostics are probably

5% to 7%, and,

you know, 3% is probably very generous

for people who are enthusiastic
about its use.

Why do you think that is?

Is it a pushback against what we're seeing

on social media?

It's very evident.

You look at one TikTok, and

that's all you will see
now for the next week.

Is it elements of that?

Is it medicine getting ahead of its skis?

What do you think is...

what do you think is sort of

causing that sort of divide?

So I think medicine as a whole is

relatively conservative.

You know, based on the fact that...

one of the main tenets
of the Hippocratic Oath

is that we do no harm, right?

And so we want to make sure...

Like,

medicine as a whole
is a very slow behemoth.

You really need to get a lot of data.

You need to really justify it.

You need to prove it well to your peers,

to everybody, before things change.

And nobody wants to be that person that,

you know, sort of supports a thing

and then we find out later
for it to be a disaster.

And I think that part of that is...

So that's just
the basic background for medicine.

But then I think

that there's probably even more hesitance

as a result of what's happened
over the last five years

with COVID. Because you see,

for example, that we had a pandemic.

People, the governments
and physicians as a whole,

we had this novel thing.

We were worried about
what's going to happen to people.

Are we going to have, you know,

a mass extinction event type of thing?

And so they implemented
these mRNA vaccines that,

you know,

those particular vaccines
did not have a lot of study.

mRNA vaccines in general have been

something that's been studied

for many years, but

those particular ones
did not have a lot of study,

and there was a lot of pushback
about that.

And so I think, as a group now,

medicine is kind of looking at,

"We're not just going to
promote this thing.

You know, we've kind of been
once bitten, twice shy.

So we're not interested in that.

We're going to take our time.

We're going to check this."

Because that was one of...

People who are anti-vax,

that was one of their big things.

"Oh, these are untested,
and you're forcing this on us."

And it's funny,

because I think it's ironic

that so many of the same people

who would not take the mRNA vaccine

because it was "untested"

are willing to just buy
something off of Instagram

and inject it, no questions asked.

Indeed. And they don't even know

the provenance
of where it's actually come from,

let alone what some of the potential,

you know, shortcomings could be.

I mean,

you know, as somebody who is

working directly with people
who are showing

an interest in peptides, what

do you think is the most

sort of common misconception that

you come up against from

a medical practice perspective?

I think the most common misconception...

And I'll have to caveat this by saying

I don't know if

this is a fact because
we don't have enough data.

But the most common misconception,
I would say,

is just the degree of efficacy

of the peptides. Like,

people come to me and they tell me

that they've been using it,

and they are telling me
that their rotator cuff tear,

with

a rotator cuff tendon
that was retracted as seen on MRI,

they injected peptides and

it reattached.

It healed, right?

Or things like this.

And I'm like...

And I see these people. Listen,

when you have a...

if you had a small rotator cuff tear,

small and,

you know,

partial-thickness tear,
and you injected peptide,

I said, "Maybe.
Maybe there's a biological mechanism

or a physiological mechanism

by which that could heal itself."

But when you are talking a significant

full-thickness tear that is retracted,

this is no longer really
a biological problem.

This is a structural problem.

It's like you having a hole in your roof

and then trying to paint
the walls inside your house

and saying that you fixed the problem.

This doesn't happen.

So the efficacy

that people attribute to these,

I think, is a huge misconception.

And again, I will

say my disclaimer is
that we don't have the data,

so I can't really speak
to whether that is 5%

wrong or 80% wrong. But

in my own clinical experience,

I would estimate that that's

hugely overestimated.

Absolutely. Now it's our final question,

and it's the same question

we ask every guest,

and they can take it
in any direction that they want.

So, jumping forward ten years,

where do you think

the peptide sector will be, or should be?

You know,
what would that roadmap look like for you?

Well,

I think,

jumping forward ten years,

we are going to have
a better understanding

of which peptides are,

you know,

which ones are effective,
what makes them effective.

We will have better data
about the long-term use

of these peptides.

And I do think that they are going to be,

just the same way as insulin is now,

or Ozempic is...

These have now become
part of our mainstream

medical culture.
I think that we'll start to see

peptides become part
of our normal culture.

They will be standardized,

and they will become part
of our treatment algorithm.

And physicians
will become familiar with them,

and they will be starting
to prescribe them,

I think, on a regular basis.

This is, you know,

ten years is, on the one hand,
a long time,

but on the other hand, it's not that long.

And I see probably that happening

- during that time frame.
- Quite a lot of hearts and minds

that will need to be won over.

I mean, you know,

when we touch on sort of 85%,

maybe 90%, of medical professionals

in your proximity

probably sit on the more
sort of cynical side,

there is going to be a lot of,

you know, a lot of education

and a lot of advocacy
that needs to be done,

which has to be supported by, ultimately,

large amounts of robust clinical data.

Is that a fair summary?

It is, for sure.

But, like, as I said,

you know, medicine is a behemoth, and

we need the information,

the data, in order to make
the change, right?

But I do see that.
I do see that happening.

And it's funny because,

you know, one of the things
that I've talked about

in some of my video content,

I said how nobody really wants
to do this study

because

they can't recoup the money
that they spend

in doing those studies. But yet,

if you look at the peptide industry

that is available online right now,

this is a multibillion-dollar industry.

- So, you know...
- Arguably,

arguably,

there's never been a sector
with more researchers

working in it,

if we're to believe
the "research use only" label.

Yes, for sure.

So, you know,

the...

somebody's going...
They may not have figured it out yet,

but somebody will. There is a way for,

you know,

pharmaceutical companies
to make money from this.

And once they figure that out,

then we'll actually get
the research data, right?

Like, somebody had to do that
with Ozempic,

right?

And then

they turned into
a multibillion-dollar company, right?

Yeah.

I mean,

there is no doubt
that this is a common argument

in the peptide space,
that they can't be patented.

Therefore, nobody will ever do
the clinical work,

because then there

isn't any upside for them
doing the clinical work.

I mean, ultimately,

these things can

have patentable opportunity around them.

There can be clinical work
done around them.

That's what Eli Lilly is doing right now

as it pushes through on its,

you know, its GLP-3 propositions.

I think where it becomes
sort of quite interesting

is where we have compounds where,

you know,
the genie is already out of the bottle,

whether there's more

sort of real-world evidence gathering

which needs to take place.

Because arguably, you know,

certainly this is

more of a US-centric

challenge.

If we move to a market where,

you know, six or seven of these

kind of restricted compounds

can go into a compounding pharmacy,

then there is going to be
a huge amount of people

who are taking them under,

you know, doctor supervision.

I think the opportunity
and the responsibility

for people is to gather that information

and to report that information back

and to build up, you know,

transparency and good quality
and provenance of data.

No doubt. I agree.

And I think,

you know, it's got to start someplace.

That's as good a place as any.

And then I do think
that there will be enough...

As I mentioned,

I think there's going to be...

there's so much demand

that eventually people
are not going to be able to

deny this, right?

So it'll just be a question of, okay,

well, how do we get this data

so that we can provide
the clearest evidence

and the clearest support that we can and,

you know, give people
the best information about dosing,

duration and side effects?

Chris, thank you very much
for your sensible,

pragmatic at times, and agnostic

views on peptides.

Not a problem.
Thank you very much for having me.

- I enjoyed this conversation immensely.
- Thank you.